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Occurrence of pulmonary embolism in a patient with mild clinical expression of COVID-19
Dear Editor,
We would like to give a further contribution to the current issue
concerning the occurrence of a hypercoagulable state and its clinical
consequence in the course of the COVID-19 by reporting the clinical
case of one of the authors (CV).
CV, a 70 y.o. man, became feverish in the evening of March 11th,
but fever completely disappeared the day after. In the following days
CV complained of sore throat, severe myalgia, weakness and anorexia.
Cough or shortness of breath was not present. Since CV lives in Milan
and is a medical doctor having contacts with a lot of people, a SARS-
CoV-2 infection was supposed. In accordance with the recommenda-
tions of the National and Regional Health Authority for the pandemic
outbreak, CV decided to stay at home, assuming only intermittent
therapy to improve myalgia (diclofenac). A week after the symptoms
progressively improved and only mild sore throat persisted.
On April 2nd dyspnoea, together with increased cardiac rate
(110–120 bpm), suddenly appeared and then it was decided to call on
the Emergency Room of the Ospedale Maggiore-Policlinico of the
University of Milan. Here an arterial blood sample was taken that re-
vealed the signs of respiratory alkalosis together with metabolic
acidosis. A chest-x-ray film did not show significant abnormalities. A
computed tomography (CT) of the chest with contrast agent was per-
formed. It showed the presence of bilateral pulmonary embolism (PE)
involving secondary and segmental branches (Fig. 1). Only few limited
sub-pleural ground glass areas were noted. Peripheral blood examina-
tion documented the presence of very high level of D-dimer (more than
5 times the normal values), with light reduction of platelet count and a
C-reactive protein just above the normal limits.
CV was transferred to an internal medicine unit reserved to COVID-
19 suspected patients, since the clinical condition did not require ad-
mission to an intensive care unit (ICU). Here treatment with antic-
oagulant therapy (enoxaparin 8000 U BID) was introduced, and a re-
spiratory support with low flux oxygen (FiO2 24%) was given. No signs
of significant PAPs increase or overcharge of the right cardiac ventricle
were observed on echocardiographic examination. No signs of deep
venous thrombosis were found on Doppler examination. A nasal-phar-
yngeal swab sample taken ad the admission time confirmed the pre-
sence of SARS-CoV-2 infection.
Rapid improvement of respiratory function and reduction of cardiac
rate was recorded in the following few days. CV was then discharged by
the hospital on April 7th since oxygen support was no more needed.
Anticoagulant therapy was shifted to apixaban 5 mg BID to be con-
tinued for six months.
The occurrence of a hypercoagulable state in the course of critically
ill ICU patients with COVID-19 is an emerging issue [1]. This may in-
duce al large variety of intravascular thrombotic phenomena ranging
from fatal disseminated intravascular coagulation (DIC) to a more
limited venous and arterial thrombosis, namely PE. It has been sug-
gested that many deaths during COVID-19 in patients requiring in-
tensive care unit (ICU) admission could be ascribed to this coagulo-
pathy, and overall to incidental DIC in patients with severe pneumonitis
[1]. In the Wuhan cohort, during pandemic outbreak, the presence of
coagulation cascade activation was noted [2], and, in a retrospective
study [3], it was reported that prophylactic heparin treatment in ICU-
admitted patients with proven COVID-19 pneumonia reduced the
mortality rate in comparison to the patients that did not receive it.
It has been suggested that infection-related release of large amounts
of inflammatory cytokines can cause an endothelial damage, activate
the coagulation cascade, and consequently may predispose to throm-
botic events that may also occur in pulmonary vasculature [4]. This
event may probably contribute to the progression of pulmonary dys-
function and increase the mortality rate in these patients.
These data pushed the International Society on Thrombosis and
Haemostasis to propose a guidance on diagnostic and therapeutic ap-
proach to coagulopathy in COVID-19 [1]. These guidelines suggest to
perform D-dimer, prothrombin time, and platelet count in all patients
who present with COVID-19, and to admit to the hospital those patients
with important signs of coagulopathy (namely very high levels of D-
dimer), also in absence of other concerns. In view of the risk of oc-
currence of such a hypercoagulable state, the use of prophylactic dose
of low molecular weight heparin in all the patients requiring hospita-
lization for COVID-19, including those not requiring ICU has been
proposed [1]. A recent study on ICU-admitted patients with COVID-19
pneumonia has shown that thrombotic events were recorded in 31% of
them with a large prevalence of PE (81%). It is worth noting that all of
these patients received thromboprophylaxis [5]. As a consequence of
these data, an early initiation of therapeutic anticoagulation in criti-
cally ill patients with significant coagulation abnormalities could be
indicated [4,6]. Furthermore, a more extensive use of CT pulmonary
angiography in order to document incidental PE should be considered
in all hospitalized patients with laboratory signs of coagulopathy [7].
The present case report may suggest some additional considerations
regarding the therapeutic and clinical approach to SARS-CoV-2-infected
patients.
a. Even patients with mild clinical manifestations, not requiring hos-
pital admission may develop PE in the course of COVID-19. This
suggests that inflammation-related endothelial damage could not be
related to the presence and severity of COVID-19 pneumonia.
Furthermore, the performance of coagulation tests could be in-
dicated in all patients having certain and suspected SARS-CoV-2
infection.
b. Hypercoagulable state may persist for long time and also induce late
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thromboembolic events.
c. At least prophylactic dose of anticoagulant therapy could be in-
troduced in all patients with COVID-19, including non-hospitalized
patients.
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Fig. 1. CT chest showing bilateral pulmonary embolism involving secondary and segmental branches.
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